古塞库单抗与阿达木单抗治疗银屑病的疗效比较：随机对照研究的荟萃分析
Efficacy of guselkumab compared with adalimumab for psoriasis: a meta-analysis of randomized controlled studies.
作者信息
Fu Hongyi, Guo Jing
机构信息
Department of Medical Cosmetology Center, the first branch of The First Affilliated Hospital of Chongqing Medical University, Chongqing, China.
Department of Dermatology, Youyang People's Hospital, Chongqing, China.
出版信息
Postepy Dermatol Alergol. 2022 Oct;39(5):953-958. doi: 10.5114/ada.2022.120886. Epub 2022 Nov 9.
INTRODUCTION
The efficacy of guselkumab versus adalimumab for psoriasis remains controversial.
AIM
We conducted a systematic review and meta-analysis to explore the influence of guselkumab versus adalimumab on treatment efficacy for psoriasis.
MATERIAL AND METHODS
We have searched PubMed, Embase, Web of Science, EBSCO, and Cochrane library databases for randomized controlled trials (RCTs) published until March 2021 and assessing the efficacy and safety of guselkumab versus adalimumab for psoriasis. This meta-analysis was performed using the random-effects model.
RESULTS
Three RCTs were included in the meta-analysis. Overall, compared with adalimumab for psoriasis, guselkumab was associated with improved PASI 100 (OR = 2.18; 95% CI: 1.47 to 3.23; = 0.0001), PASI 90 (OR = 2.63; 95% CI: 2.11 to 3.27; < 0.00001), PASI 75 (OR = 3.10; 95% CI: 2.35 to 4.08; < 0.00001) and PGA 0/1 (OR = 2.04; 95% CI: 1.26 to 3.31; = 0.004), as well as decreased DLQI (SMD = -0.24; 95% CI: -0.34 to -0.13; < 0.00001). In addition, guselkumab resulted in higher DLQI score 0/1 (OR = 1.88; 95% CI: 1.51 to 2.33; < 0.00001) than adalimumab.
CONCLUSIONS
Guselkumab showed better efficacy than adalimumab for psoriasis.
引言
古塞库单抗与阿达木单抗治疗银屑病的疗效仍存在争议。
目的
我们进行了一项系统评价和荟萃分析，以探讨古塞库单抗与阿达木单抗对银屑病治疗疗效的影响。
材料与方法
我们检索了PubMed、Embase、Web of Science、EBSCO和Cochrane图书馆数据库，查找截至2021年3月发表的随机对照试验（RCT），评估古塞库单抗与阿达木单抗治疗银屑病的疗效和安全性。本荟萃分析采用随机效应模型。
结果
三项RCT纳入了荟萃分析。总体而言,与阿达木单抗治疗银屑病相比，古塞库单抗与达到PASI 100改善（OR = 2.18；95% CI：1.47至3.23；P = 0.0001）、PASI 90改善（OR = 2.63；95% CI：2.11至3.27；P < 0.00001）、PASI 75改善（OR = 3.10；95% CI：2.35至4.08；P < 0.00001）以及PGA 0/1改善（OR = 2.04；95% CI：1.26至3.31；P = 0.004）相关，同时与较低的DLQI（SMD = -0.24；95% CI：-0.34至-0.13；P < 0.00001）相关。此外，与阿达木单抗相比，古塞库单抗导致更高的DLQI评分0/1（OR = 1.88；95% CI：1.51至2.33；P < 0.00001）。
结论
对于银屑病，古塞库单抗显示出比阿达木单抗更好的疗效。
Zotero 插件